Critical Contrast: Unicycive Therapeutics (NASDAQ:UNCY) vs. Targeted Medical Pharma (OTCMKTS:TRGM)

Targeted Medical Pharma (OTCMKTS:TRGM) and Unicycive Therapeutics (NASDAQ:UNCY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for Targeted Medical Pharma and Unicycive Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Targeted Medical Pharma	0	0	0	0	0.00
Unicycive Therapeutics	0	0	4	1	3.20

Unicycive Therapeutics has a consensus price target of $5.50, indicating a potential upside of 810.60%. Given Unicycive Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Targeted Medical Pharma.

Earnings and Valuation

This table compares Targeted Medical Pharma and Unicycive Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Targeted Medical Pharma	N/A	N/A	N/A	N/A	N/A
Unicycive Therapeutics	$680,000.00	92.20	-$30.54 million	($0.97)	-0.62

Targeted Medical Pharma has higher earnings, but lower revenue than Unicycive Therapeutics.

Profitability

This table compares Targeted Medical Pharma and Unicycive Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Targeted Medical Pharma	N/A	N/A	N/A
Unicycive Therapeutics	N/A	N/A	-29.88%

Insider and Institutional Ownership

40.4% of Unicycive Therapeutics shares are owned by institutional investors. 69.2% of Targeted Medical Pharma shares are owned by insiders. Comparatively, 24.1% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Unicycive Therapeutics beats Targeted Medical Pharma on 6 of the 8 factors compared between the two stocks.

About Targeted Medical Pharma

Targeted Medical Pharma, Inc., a specialty pharmaceutical company, doing business as Physician Therapeutics, develops and commercializes amino acid based medications to physicians, pharmacies, and patients in the United States. It offers a line of patented amino acid based medical food products, dietary supplements, and generic drugs primarily for the treatment of metabolic syndrome/obesity; sleep disorders associated with anxiety; hypertension; viral infections; cognitive disorders/fatigue; sleep disorders associated with depression, fibromyalgia, and PTSD; pain disorders and inflammatory conditions/fibromyalgia; osteoarthritis and joint disorders; and peripheral neuropathy. The company also provides a proprietary billing process and supporting software (PDRx) that facilitates physician dispensing; provides inventory control; and assists regulatory reporting. In addition, it offers billing and collection services relating to its products on behalf of dispensing physician clients to private insurance and workers' compensation insurance. Targeted Medical Pharma, Inc. distributes its products through a network of distributors and an internal sales force that sells products directly to dispensing physician clients. The company was formerly known as Targeted Medical Foods and changed its name to Targeted Medical Pharma, Inc. in 2006. Targeted Medical Pharma, Inc. was founded in 1996 and is headquartered in Los Angeles, California.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.